Company / SG&A Expense
Biofrontera Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$33.8M
FY2025
5-year range
$17.7M / $36.5M
FY2021-FY2025
Trend
+82.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $34M.
Based on SEC 10-K filings.
$34M in FY2025 with a 3-year CAGR of -2.5%.
Improved from $35M to $34M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -2.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -2.5%, indicating a declining trend.
- In FY2025, sg&a expense increased 82.8% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.8M | +82.8% |
| FY2024 | $18.5M | -47.4% |
| FY2023 | $35.1M | -3.8% |
| FY2022 | $36.5M | +106.2% |
| FY2021 | $17.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026